| Mean DAS (SE) | Low disease activity | Remission |
---|---|---|---|
At year 7 (still on infliximab) | 3.0 (0.1) | 60.90% | 45.50% |
At discontinuation due to ineffectiveness | 5.2 (0.2) | 10.50% | 5.30% |
At discontinuation due to elective reason | 2.9 (0.1) | 61.70% | 46.70% |
At discontinuation due to safety issue | 4.3 (0.7) | 33.30% | 13.60% |